miR-29 is a major regulator of genes associated with pulmonary fibrosis - PubMed (original) (raw)

miR-29 is a major regulator of genes associated with pulmonary fibrosis

Leah Cushing et al. Am J Respir Cell Mol Biol. 2011 Aug.

Abstract

MicroRNAs (miRNA) are small regulatory RNAs that control gene expression by translational suppression and destabilization of target mRNAs. There is increasing evidence that miRNAs regulate genes associated with fibrosis in organs, such as the heart, kidney, liver, and the lung. In a large-scale screening for miRNAs potentially involved in bleomycin-induced fibrosis, we found expression of miR-29 family members significantly reduced in fibrotic lungs. Analysis of normal lungs showed the presence of miR-29 in subsets of interstitial cells of the alveolar wall, pleura, and at the entrance of the alveolar duct, known sites of pulmonary fibrosis. miR-29 levels inversely correlated with the expression levels of profibrotic target genes and the severity of the fibrosis. To study the impact of miR-29 down-regulation in the lung interstitium, we characterized gene expression profiles of human fetal lung fibroblast IMR-90 cells in which endogenous miR-29 was knocked down. This confirmed the derepression of reported miR-29 targets, including several collagens, but also revealed up-regulation of a large number of previously unrecognized extracellular matrix-associated and remodeling genes. Moreover, we found that miR-29 is suppressed by transforming growth factor (TGF)-β1 in these cells, and that many fibrosis-associated genes up-regulated by TGF-β1 are derepressed by miR-29 knockdown. Interestingly, a comparison of TGF-β1 and miR-29 targets revealed that miR-29 controls an additional subset of fibrosis-related genes, including laminins and integrins, independent of TGF-β1. Together, these strongly suggest a role of miR-29 in the pathogenesis of pulmonary fibrosis. miR-29 may be a potential new therapeutic target for this disease.

PubMed Disclaimer

Figures

Figure 1.

Figure 1.

Expression of miR-29 in normal and bleomycin-treated mouse lungs. (A) Trichrome staining showed subpleural lesions 7 days after bleomycin injection; progressive fibrosis is shown from Day (D) 7 to D28 with increased collagen (Col) staining; a large portion of these lesions were resolved at D70 and D140. (B) miR-29 family members are down-regulated in bleomycin-treated lungs (*P < 0.05). (C). Levels of miR-29 detected by Northern blot increases during lung development, with highest levels in adult lung. Expression of miR-29 is higher in fibroblast cells (Mlg and NIH3T3) than in epithelial cells (E10, type I–like cells). (D) miR-29 is expressed in the alveolar wall and in pleura. (E1_–_E3) miR-29 is expressed in mesenchymal cells at the entrance of the alveolar duct and costains with α-SMA (B1, miR-29 in situ hybridization [ISH]; B2, α-SMA immunohistochemistry; B3, merged image). Green arrow, subpleural fibrotic lesion; green arrowhead, miR-29–expressing cells; red arrowhead, cells with low or undetectable miR-29 expression.

Figure 2.

Figure 2.

Levels of miR-29 inversely correlated with its downstream targets in bleomycin-induced pulmonary fibrosis. (A) Levels of miR-29 are gradually reduced after bleomycin injection, reaching lowest levels at D28, and then gradually recover at D70 and D140. Levels of Col3A1 and Col4A1, targets of miR-29, are inversely correlated with miR-29 levels in this process. (B and C) Down-regulation of miR-29 in cells at the entrance of alveolar ducts is found in bleomycin-treated lungs (C) as compared with controls (B), inversely correlating with collagen staining in these cells (D and E). (B and C) ISH of miR-29c; (D and E) Masson's trichrome staining; *P < 0.05.

Figure 3.

Figure 3.

Reduced expression of miR-29 in subepithelial mesenchymal cells of terminal bronchioles was observed in bleomycin-treated lungs (F) as compared with lungs from mice receiving PBS injection (C). This inversely correlates with collagen staining (B and E) and thickening of subepithelial structures (A and D).

Figure 4.

Figure 4.

miR-29–mediated regulation of target gene expression. (A) Knockdown of miR-29 expression by locked nucleotide acid (LNA) knockdown oligos. Expression of miR-29a, miR-29b, and miR-29c were significantly reduced in IMR-90 cells (human fetal lung fibroblasts) transfected with LNA knockdown oligos either for miR-29a or miR-29b or miR-29c, but not with scrambled LNA oligos. (B) mRNA levels of COL4A1 and Nidgen (NID) 1 are significantly decreased in IMR-90 cells transiently transfected with miR-29 mimic as compared with control oligos. (C) miR-29 knockdown resulted in a significantly increased level of COL1A1 protein, whereas increased miR-29 reduced COL1A1 protein. (D) The level of total soluble collagen in the culture medium is increased in miR-29 knockdown IMR-90 cells.

Figure 5.

Figure 5.

ITGA11, ADAMTS9, ADAM12, and NID1 are direct targets of miR-29. FG293 cells were cotransfected with individual 3′ untranslated region (UTR) luciferase reporters with wild-type (wt) or mutated (mut) miR-29–binding sites, along with miRNA mimics of miR-29 or miR-365. Firefly luciferase activity from the same construct was used to normalize and to generate relative activity of Renilla luciferase, which was subject to the regulation of cloned 3′ UTR. miR-29 significantly suppressed luciferase activities of reporters harboring wild-type 3′ UTR sequences, but not for reporters with mutated miR-29–binding sites. miR-365, an unrelated miRNA, has no significant effect on the luciferase activities of reporters with either wild-type or mutant 3′ UTRs.

Figure 6.

Figure 6.

Expression of miR-29 is down-regulated by transforming growth factor (TGF)–β1 in IMR-90 cells. Down-regulation of miR-29a, -b, and -c were detected by qRT-PCR array (A), and confirmed by quantitative real-time PCR and Northern blot (B and C).

Similar articles

Cited by

References

    1. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J 2007;30:835–839. - PubMed
    1. Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008;294:L152–L160. - PubMed
    1. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199–210. - PMC - PubMed
    1. Strieter RM, Mehrad B. New mechanisms of pulmonary fibrosis. Chest 2009;136:1364–1370. - PMC - PubMed
    1. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215–233. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources